TY - T1的生存差异帕金森症和帕金森病精神病患者:一项基于人群的研究(2006 - 2015)。(p4 - 11.007) JF 首页-神经学乔-神经学六世- 98 - 18补充SP - 1739 AU -科尔刺伤AU -埃Camerucci盟艾丹马伦AU -格雷琴Ahrens盟又是Turcano AU -詹姆斯·鲍尔AU -布拉德利Boeve盟Rodolfo Savica Y1 - 2022/05/03 UR - //www.ez-admanager.com/content/98/18_Supplement/1739.abstract N2 -目的:探讨存活率和症状的帕金森病(PD)和帕金森病精神病(PDP)。背景:在PD患者和精神病是常见可能会影响他们的生活质量。然而,很少有研究调查的影响精神病在PD生存在以人群为基础的队列。设计/方法:我们使用了罗彻斯特流行病学项目定义一个人口基数的PD奥姆斯特德县2006 - 2015 MN。运动障碍专家审查所有的临床记录确认PD的诊断。被诊断为PDP使用研究所/ NIMH统一标准。结果:我们发现69例PDP的225例PD (31%)。任何原因的死亡率高于PDP相比PD (HR = 4.79, p = 0.005)男性和女性之间没有显著差异;然而,5年增加PD发病年龄与死亡率的风险更高(HR = 2.39,术中;0.001)。 PDP patients showed higher rates of cognitive impairment (40.6% vs 25.6%, p=0.024) and orthostatic hypotension (26.1% vs 14.7%, p=0.042) as compared to PD; no differences in rates of falls (p=0.63), chronic dizziness (p=0.54), or somnolence (p=0.13) were observed. Of the 69 PDP patients (n=69), n=31 (45%) were prescribed antipsychotic treatment; there were no observed statistically significant differences between PDP treated vs untreated with antipsychotic medications in terms of: falls (p= 0.40), dizziness (p= 0.70), somnolence (p=0.59), cognitive impairment (p=0.17), or orthostatic hypotension (p=0.44).Conclusions: Psychosis is associated with a higher risk of all-causes mortality in PD; age of onset of PD influences the mortality risk. PDP may be at greater risk of developing neuropsychiatric symptoms (e.g. cognitive impairment) and/or additional nonmotor symptoms (e.g. orthostatic hypotension) as compared to PD without psychosis. In this cohort, 55% of PDP patients were not treated with antipsychotics.Disclosure: Mr. Stang has nothing to disclose. Dr. Camerucci has nothing to disclose. Aidan Mullan has nothing to disclose. Ms. Ahrens has nothing to disclose. Dr. Turcano has nothing to disclose. The institution of Dr. Bower has received research support from Abbvie. Dr. Boeve has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Rainwater Charitable Foundation. The institution of Dr. Boeve has received research support from Biogen. The institution of Dr. Boeve has received research support from EIP Pharma. The institution of Dr. Boeve has received research support from Alector. The institution of Dr. Boeve has received research support from GE Healthcare. Dr. Boeve has received publishing royalties from a publication relating to health care. The institution of Dr. Savica has received research support from ACADIA Pharmaceuticals, Inc. ER -